Login to Your Account

Biogen options Rodin buy with $485M R&D deal, equity investment

By Michael Fitzhugh
Staff Writer

Wednesday, January 6, 2016

Rodin Therapeutics Inc. has landed a multi-year neuronal epigenetics R&D deal with Biogen Inc. that includes an undisclosed up-front payment for an option to buy the small cognitive disorders specialist as well as potential milestone payments of up to $485 million should the acquisition come to pass.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription